ReviewGastroenterology report2015
Refractory gastroesophageal reflux disease.
Review in Gastroenterology report, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03476265 (Evaluation of Gastroesophageal Reflux Disease - Health Related Quality of Life After Lower Esophageal Sphincter), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Gastroesophageal Reflux Disease - Health Related Quality of Life After Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motilitygus (IEM)
Who cites it
30 citing papers in PubMed.
- A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial.Acta bio-medica : Atenei Parmensis · 2020Trial
- Anti-reflux mucosectomy using a cap-assisted endoscopic mucosal resection method for refractory gastroesophageal disease: a prospective feasibility study.Surgical endoscopy · 2020Trial
- Peroral Endoscopic Cardial Constriction with Band Ligation for Gastroesophageal Reflux Disease: A Prospective Pilot Study.Endoscopy international open · 2026Article
- Effects of the Transcutaneous Electrical Stimulation System on Heartburn, Regurgitation and Esophageal Acid Exposure in GERD Patients-An Uncontrolled Feasibility Study.Neurogastroenterology and motility · 2025Article
- Improving treatment of people with gastro-esophageal reflux disease refractory to proton pump inhibitors.Communications medicine · 2024Review
- Prevalence and risk factors of gastroesophageal reflux disease symptoms in Mazandaran, North of Iran: A Tabari cohort study.Caspian journal of internal medicine · 2024Article
- Pilot study of an endoluminal-suturing device as a treatment for patients with gastroesophageal reflux disease.Endoscopy international open · 2023Article
- New Perspectives in Endoscopic Treatment of Gastroesophageal Reflux Disease.Diagnostics (Basel, Switzerland) · 2023Review
- Anti-reflux mucosectomy for refractory gastroesophageal reflux disease: a systematic review and meta-analysis.Endoscopy international open · 2022Review
- Recent Advances in the Endoscopic Management of Gastro-esophageal Reflux Disorder: A Review of Literature.Cureus · 2022Review
- Berberine Alleviates Gastroesophageal Reflux-Induced Airway Hyperresponsiveness in a Transient Receptor Potential A1-Dependent Manner.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Beyond the Eckardt Score: Patient-Reported Outcomes Measures in Esophageal Disorders.Current gastroenterology reports · 2021Review
- Effect of the transcutaneous electrical stimulation system on esophageal-acid exposure in patients non-responsive to once-daily proton-pump inhibitor: proof-of-concept study.Gastroenterology report · 2021Article
- CYP2C19 genotype variability in patients with refractory gastroesophageal reflux after per-oral endoscopic myotomy (POEM).Endoscopy international open · 2021Article
- Role ofFood science & nutrition · 2021Article
- Treatment of Refractory Gastroesophageal Reflux Disease.Gastroenterology & hepatology · 2020Article
- Atypical dysphagia with end-stage oesophageal disease 30 years post Angelchik device placement in a 72-year-old man.BMJ case reports · 2020Article
- Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility-a safety and efficacy study.Surgical endoscopy · 2019Article
- The Effect of Zero Copayments on Medication Adherence in a Community Pharmacy Setting.Innovations in pharmacy · 2019Article
- Use of Esophageal pH Monitoring to Minimize Proton-Pump Inhibitor Utilization in Patients with Gastroesophageal Reflux Symptoms.Digestive diseases and sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroesophageal reflux disease (GERD) is a condition that develops when the reflux of stomach contents into the esophagus causes troublesome symptoms, esophageal injury, and/or complications. Use of proton pump inhibitors (PPI) remains the standard therapy for GERD and is effective in most patients. Those whose symptoms are refractory to PPIs should be evaluated further and other treatment options should be considered, according to individual patient characteristics. Response to PPIs could be total (no symptoms), partial (residual breakthrough symptoms), or absent (no change in symptoms). Patients experiencing complete response do not usually need further management. Patients with partial response can be treated surgically or by using emerging endoscopic therapies. Patients who exhibit no response to PPI need further evaluation to rule out other causes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.